Table 2. The cumulative incidences of neutrophil engraftment, platelet engraftment, acute GVHD, and chronic GVHD according to donor groups

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Engraftment and GVHD | MSD | WM-URD | PM-URD | *P* |
| Cumulative incidence (95% CI) | | |
| Neutrophil engraftment at day 28 | 99.3% (95.4–99.9) | 100% | 97.0% (59.8–99.8) | 0.79 |
| Median (range) | 12 (5–21) | 11 (8–26) | 11 (10–21) |  |
| Platelet engraftment at day 28 | 88.0% (81.5–92.3) | 81.9% (70.7–89.2) | 75.8% (56.4–87.4) | 0.48 |
| Median days (range) | 16 (7–99) | 17 (7–433) | 18 (7–49) |  |
| Acute GVHD at day 100 |  |  |  |  |
| Grade II-IV1,2,3 | 8.5% (4.8–13.6) | 36.1% (25.1–47.2) | 57.6% (38.6–72.6) | < 0.01 |
| Grade III-IV1,2 | 7% (0.1–3.3) | 9.8% (4.3–18.1) | 18.2% (7.2–33.1) | < 0.01 |
| Chronic GVHD at 6 years |  |  |  |  |
| Mild-to-severe1,2 | 8.6% (4.8–13.8) | 43.4% (31.6–54.6) | 36.6% (18.0–77.5) | < 0.01 |
| Moderate-to-severe1,2 | 2.6% (0.9–6.2) | 30.6% (20.3–41.4) | 27.3% (13.4–43.2) | < 0.01 |
| Severe1,2 | 0.7% (0.1–3.6) | 12.5% (6.1–21.3) | 12.1% (3.7–25.8) | < 0.01 |

1 indicates *P* < 0.01 between the MSD and the WM-URD groups, 2 indicates *P* < 0.01 between the MSD and the PM-URD groups, and 3 indicates *P* < 0.01 between the WM-URD and the PM-URD groups.

*GVHD* graft-versus-host disease, *MSD* matched sibling donor, *WM-URD* well-matched unrelated donor, *PM-URD* partially matched unrelated donor, *CI* = confidence interval